戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rom alpha-granules drives the development of bone marrow fibrosis.
2 nules within blood platelets and progressive bone marrow fibrosis.
3 pathic disorder characterized by progressive bone marrow fibrosis.
4 dly reduced extramedullary hematopoeisis and bone marrow fibrosis.
5 a significant regression of splenomegaly and bone marrow fibrosis.
6  appear to be associated with progression to bone marrow fibrosis.
7 ropoiesis, extramedullary hematopoiesis, and bone marrow fibrosis and osteosclerosis.
8 transforming growth factor beta1 in inducing bone marrow fibrosis and stromal cell-derived osteoprote
9 acterized by megakaryocyte (MK) hyperplasia, bone marrow fibrosis, and abnormal stem cell trafficking
10 m characterised by splenomegaly, cytopenias, bone marrow fibrosis, and debilitating symptoms includin
11 der that leads to ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis.
12 who had neutropenia, neutrophil dysfunction, bone marrow fibrosis, and nephromegaly.
13                                              Bone marrow fibrosis (BMF) develops in various hematolog
14 vidence of extramedullary hematopoiesis, and bone marrow fibrosis, but no lymphoproliferative disease
15 locytosis, extramedullary hematopoiesis, and bone marrow fibrosis, but not thrombocytosis.
16 olonies, larger spleen size, and accelerated bone marrow fibrosis compared with heterozygous Jak2V617
17 ed blood counts, spleen weights, and reduced bone marrow fibrosis compared with ruxolitinib alone.
18 s secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other causes.
19  < 100 x 10(9)/L, circulating blasts >/= 2%, bone marrow fibrosis grade >/= 2, constitutional symptom
20 een implicated in the etiology of idiopathic bone marrow fibrosis (IMF).
21  mass in PV, a high platelet count in ET and bone marrow fibrosis in PMF, respectively.
22 okines, reduced disease burden, and reversed bone marrow fibrosis in vivo.
23                                              Bone marrow fibrosis is the result of a complex and not
24 mary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary
25 cidence, degree, and prognostic relevance of bone marrow fibrosis obtained at time of initial diagnos
26                   No improvement was seen in bone marrow fibrosis or JAK2(V617F) allele burden.
27 athologic or cytogenetic remissions, reverse bone marrow fibrosis, or improve survival over best supp
28                                              Bone marrow fibrosis remains an area of active study, al
29 lostim produced a dose-dependent increase in bone marrow fibrosis that resolved after treatment withd
30                                    Extensive bone marrow fibrosis was found in 23 patients (62%).
31                                              Bone marrow fibrosis was reversed in all 4 patients who
32 e events (eg, thrombosis, hepatobiliary, and bone marrow fibrosis) were infrequent.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。